Table 5.
Summary of the results of some studies regarding the correlation of fecal calprotectin with endoscopic activity in IBD patients.
| Number of IBD patients | Age group | Study location | Used endoscopic activity index | Correlation coefficient (r) | Reference |
|---|---|---|---|---|---|
| 77 (CD) | Adults | Finland | CDEIS | 0.729 | [67], |
| 22 (UC) | Adults | Iran | UCEIS | 0.798 | [47], |
| 134 (UC) | Adults | Switzerland | Rachmilewitz | 0.834 | [69], |
| 140 (CD) | Adults | Switzerland | SES-CD | 0.750 | [39], |
| 228 (UC) | Adults | Switzerland | Modified Baron Score | 0.821 | [70], |
| 31 (UC) | Adults | Germany | Rachmilewitz | 0.510 | [84], |
| 164 (CD) | Adults | USA and Canada | SES-CD | 0.450 | [85], |
| 31 (UC) | Adults | Japan | Matts | 0.810 | [86], |
| 31 (CD) | Adults | Italy | SES-CD | 0.480 | [87], |
| 46 (UC) | Adults | Italy | Mayo score | 0.511 | [87], |
| 80 (CD) | Adults | Brazil | SES-CD | 0.450 | [88], |
| 54 (CD) | Adults | France | CDEIS | 0.740 | [89], |
| 32 (UC) | Adults | France | Mayo score | 0.610 | [89], |
| 181 (UC) | Adults | South Korea | UCEIS | 0.430 | [90], |